MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.06
-0.98
-3.37%
Closed 17:26 09/30 EDT
OPEN
29.16
PREV CLOSE
29.04
HIGH
29.37
LOW
27.69
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
39.96
52 WEEK LOW
14.01
MARKET CAP
1.75B
P/E (TTM)
-11.2159
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma
Neurocrine presents encouraging three-year data for Parkinson’s treatment.Avinger receives FDA approval for Ocelaris.Editas bounces on favorable CRISPR patent ruling.
Seekingalpha · 09/18 15:07
Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of Vienna, Emmanuelle Charpentier
GlobeNewswire · 09/11 12:00
Why Is Editas (EDIT) Down 17.3% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 15:32
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference Panel: Innovation in Cell Therapy
GlobeNewswire · 09/04 12:00
Editas Medicine Review Plus Now - Better Choice Of PTC Therapeutics
In Late October last year we subjected Editas Medicine to an investment behavioral analysis because its developmental approach relies on genome editing.Then (before COVID-19) the analysis appeared quite promising of near-term capital gains under the discipline of TERMD portfolio management, in comparison to other biotech developers.The EDIT forecast of +20% gain was attained and pocketed in less than a month. Now, is reinvestment in EDIT as attractive again as similar biotech developer alternatives?With over 400 biotech-developer stocks available we once more use the behavior of investors – via their Yahoo Finance research-reading interests – in combing appropriate comparisons of alternatives.Enough change in institutional investment interest near-term has occurred to consider PTCT and XLRN more interesting and productive near-term capital gain alternatives instead.
Seekingalpha · 08/28 13:20
If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock Three Years Ago, You Could Pocket A 65% Gain Today
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Simply Wall St. · 08/26 16:54
Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag
The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.
Zacks · 08/25 16:54
Editas Scores Rare Disease Tag For EDIT-301 Sickle Cell Treatment
Editas Medicine (EDIT) has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301. This is an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for sickle cell disease.The genome
SmarterAnalyst · 08/25 08:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDIT. Analyze the recent business situations of Editas Medicine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDIT stock price target is 41.88 with a high estimate of 65.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 332
Institutional Holdings: 60.29M
% Owned: 96.83%
Shares Outstanding: 62.27M
TypeInstitutionsShares
Increased
75
7.46M
New
74
2.36M
Decreased
50
1.18M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.50%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Independent Director
James Mullen
President/Chief Executive Officer/Director
Cynthia Collins
Chief Financial Officer
Michelle Robertson
Executive Vice President/Chief Scientific Officer
Charles Albright
Senior Vice President
Harry Gill
Other
Gad Berdugo
Independent Director
Andrew Hirsch
Independent Director
Jessica Hopfield
Independent Director
David Scadden
Independent Director
Akshay Vaishnaw
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EDIT
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.